GlassScriptPhysician profile
Sydney B Long
NPI 1881924918
$6,673.44
in general payments reported to CMS, 2019-2025
25 companies · $1,010 in 2025
The $1,010 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $985 · 2020: $677 · 2021: $689 · 2022: $865 · 2023: $1,242 · 2024: $1,204 · 2025: $1,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,456.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,340.91 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $888.67 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Csl Behring | $500.22 | 2023-2025 | Hizentra, Haegarda, Andembry |
| Amgen INC. | $445.70 | 2021-2025 | Tezspire |
| Octapharma USA, INC. | $331.33 | 2019-2024 | Cutaquig |
| Genzyme Corporation | $307.56 | 2019-2023 | |
| Optinose US, INC. | $295.55 | 2019-2024 | |
| Pfizer INC. | $276.40 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $268.88 | 2019-2025 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $266.84 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $244.05 | 2020-2025 | Cuvitru, Hyqvia |
| Genentech USA, INC. | $214.60 | 2021-2024 | Xolair |
| Kaleo, INC. | $214.51 | 2019-2023 | Auvi-Q |
| Alk-Abello, INC | $205.19 | 2021-2022 | |
| Incyte Corporation | $174.32 | 2022-2025 | Opzelura |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.61 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Ars Pharmaceuticals Operations, INC. | $114.55 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $106.46 | 2023-2025 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $98.06 | 2019-2025 | |
| Grifols USA, LLC | $95.88 | 2021-2024 | Xembify |
| Shire North American Group INC | $74.70 | 2019 | |
| Ionis Pharmaceuticals, INC. | $31.62 | 2025 | Dawnzera |
| Kedrion Biopharma, INC. | $20.71 | 2024 | Kedrab, Albuked, Koate |
| Bio Products Laboratory USA, INC. | $20.05 | 2023 | Gammaplex, Coagadex |
| Aimmune Therapeutics, INC. | $17.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sydney Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.